MedPath

A Clinical Study to compare efficacy of add-on Ayurveda treatment versus Allopathy treatment in Attention deficit hyperactivity disorder.

Phase 4
Not yet recruiting
Conditions
Attention-deficit hyperactivity disorders. Ayurveda Condition: ANAVASTHITACITTATVAM (KEVALAVATA),
Registration Number
CTRI/2021/07/035308
Lead Sponsor
Central Council for Research in Ayurvedic Sciences
Brief Summary

This study is a randomized single-blind, parallel-group trial comparing the safety and efficacy of Add-on Ayurveda intervention (Ayushmana, Bramha Rasayana, and Jyotishmati Taila) and Conventional treatment (Clonidine, Methylphenidate, and Atomoxetine) daily for six months in 160 subjects (80 in each group) with Attention Deficit Hyperactivity Disorder (ADHD) that will be conducted at National Institute of Mental health and Neurosciences (NIMHANS) Bengaluru. The primary outcome measure will be Changes in Conners’ Parent Rating Scale-Revised (CPRS-R) and Conners’ Teacher Rating Scale-Revised (CTRS-R) at six months. The secondary outcome measures are Changes in the modified AIIMS- INDT ADHD tool, Changes in T scores of Child behavior Checklist, Changes in the Gut microbiota, Changes in biomarkers ofneurological implications, modification in the inter-relationships among the gut and neurological biomarkers, Changes in methylation pattern in epigenome, Changes in neuropsychological functions (Assessed on children - Arousal of attention; reaction time; sustained attention; delay aversion;planning; and executive functions such as working memory, cognitiveinhibition, set/task shifting, and changesin parent’s report on the executive functions of their children), Modulation of the functional brain network connectivity and Safety of Ayurveda interventions at six months.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
160
Inclusion Criteria
  • •Children and adolescents of both sex in age group of 6-15 years •Fulfilling DSM -5 criteria for the diagnosis of ADHD •Patients receiving treatment as per Standard of care.
  • •Patients or parent/caregiver without any psychotic disease or any mental situation which may cause the concern to properly complete the questionnaires.
  • •Patients whose can understand and fill up required forms.
Exclusion Criteria
  • Known or suspected severe mental retardation or significant learning disorder & Children with co-existing moderate – severe Neuro-psychological conditions or autism spectrum disorder.
  • Subjects who require drug therapy or hospitalization for treatment of a chronic psychiatric illness.
  • Patient with inability to swallow the medication whole, and those with any unstable medical illness.
  • Parents who do not give consent for the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1) Change in Conners Parent Rating Scale - Revised.6 Months.
2) Change in Conners Teachers Rating Scale - Revised.6 Months.
Secondary Outcome Measures
NameTimeMethod
Change in modified AIIMS-INCLEN Diagnostic tool for ADHD.6 months
Change in T scores of Child Behaviour Check List (CBCL)6 months
Change in Gut Microbiota6 months
Change in methylation pattern in epigenome6 months
Change in neuropsychological functions1) assessed on children (arousal of attention;
Changes in biomarkers of neurologicalimplications BDNF, beta endorphins and Telomere
Changes in modulation of the functional brainnetwork connectivity (during resting-state and stop-signal
Safety of Ayurveda interventions assessed clinically andin biochemical parameters
Changes in inter-relationshipsamong the gut and neurological biomarkers

Trial Locations

Locations (1)

National Institute of Mental Health and Neurosciences

🇮🇳

Bangalore, KARNATAKA, India

National Institute of Mental Health and Neurosciences
🇮🇳Bangalore, KARNATAKA, India
Dr K John Vijay Sagar
Principal investigator
9686062710
sagarjohn@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.